𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus

✍ Scribed by Hannele Yki-Järvinen

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
74 KB
Volume
18
Category
Article
ISSN
1520-7552

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitochondrial DNA variations in patients
Mitochondrial DNA variations in patients with Type 2 (non-insulin dependent) diabetes mellitus and a Welsh control population
✍ Emma J. Sherratt; Andrew W. Thomas; James W. Gagg; Aneela Majid; John C. Alcolad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 18 KB 👁 3 views

Type 2 (non-insulin dependent) diabetes mellitus may be inherited along the maternal line and a variety of mitochondrial DNA (mtDNA) variants have been implicated in the pathogenesis. We have previously reported mutations in five regions of the mitochondrial genome which encompass 11 of the 22 tRNA

Effect of insulin on blood rheology in n
Effect of insulin on blood rheology in non-diabetic subjects and in patients with type 2 diabetes mellitus
✍ Coppola, L.; Verrazzo, G.; La Marca, C.; Ziccardi, P.; Grassia, A.; Tirelli, A.; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

We evaluated the effect of insulin on platelet function, blood viscosity, and filterability in healthy subjects and in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Fifteen diabetic patients were free from cardiovascular complications (group A), while the other 15 patients had both

Monitoring of metabolic control in patie
Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination
✍ Guillausseau, P.-J. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Monitoring of metabolic control in patients with non-insulin-dependent (Type 2) diabetes (NIDDM) is usually based upon blood glucose assay in the morning (after an overnight fast) and in the postprandial state (breakfast or lunch). However, this schedule does not seek low blood glucose values, espec

Pravastatin compared to bezafibrate in t
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus
✍ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background Both HMG-CoA reductase inhibitors and ®bric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg beza®brate, a ®bric acid deriva